RBC Bioscience (ROCO:6848) ROCE %: 6.37% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6848 RBC Bioscience Corp ROCO:6848
76 GF Score
Price NT$20.50
GF Value NT$19.91
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is RBC Bioscience ROCE %?

RBC Bioscience ROCO:6848 +4.86% 76 ROCE % is 6.37% as of Dec. 2025. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$19.91 (Fairly Valued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. RBC Bioscience's annualized ROCE % for the quarter that ended in Dec. 2025 was 6.37%.

RBC Bioscience  (ROCO:6848) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

RBC Bioscience ROCE % Related Terms

RBC Bioscience ROCE % Historical Data

* Premium members only.

The historical data trend for RBC Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RBC Bioscience ROCE % Chart

RBC Bioscience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only 9.14 1.83 2.71 5.71 6.17

RBC Bioscience Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.05 6.59 4.86 5.96 6.37
ROCO:6848
76GF Score
RBC Bioscience Corp ROCO:6848
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RBC Bioscience ROCE % Calculation

RBC Bioscience's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=39.49/( ( (763.884 - 111.601) + (724.493 - 96.202) )/ 2 )
=39.49/( (652.283+628.291)/ 2 )
=39.49/640.287
=6.17 %

RBC Bioscience's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=40.436/( ( (757.615 - 116.607) + (724.493 - 96.202) )/ 2 )
=40.436/( ( 641.008 + 628.291 )/ 2 )
=40.436/634.6495
=6.37 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.37% mean?
RBC Bioscience (ROCO:6848) has a ROCE % of 6.37% as of Dec. 2025.
Is RBC Bioscience's ROCE % too high?
RBC Bioscience's current ROCE % is 6.37%. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's ROCE % compare to VRTX and REGN?
RBC Bioscience's ROCE % of 6.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. RBC Bioscience's current ROCE % is 6.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$20.50 — trading 3% above its estimated fair value. The current ROCE % is 6.37%. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current ROCE % is 6.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RBC Bioscience (ROCO:6848) Overvalued in 2026?

Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued. The current stock price of NT$20.50 is trading 3% above its estimated GF Value™ of NT$19.91. GuruFocus considers RBC Bioscience to be Fairly Valued.

Key valuation signals for ROCO:6848:

  • ROCE %: 6.37%
  • GF Value™: NT$19.91 vs. price of NT$20.50 (3% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RBC Bioscience Business Description

Address No. 15, Qiaohe Road, 15th Floor, Zhonghe District, New Taipei City, TWN, 23145
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score

Get the complete analysis for ROCO:6848

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.50
Price
NT$19.91
GF Value